Evidence map›Paper›PMID 28301559›Full record

ArticlePLoS pathogens2017

Synergy between the classical and alternative pathways of complement is essential for conferring effective protection against the pandemic influenza A(H1N1) 2009 virus infection.

Ajitanuj Rattan, Shailesh D Pawar, Renuka Nawadkar, Neeraja Kulkarni, Girdhari Lal, Jayati Mullick, Arvind Sahu

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 49 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Development and validation of nomogram for predicting the risk of transferring to the ICU for children with influenza.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Protective role of host complement system inFrontiers in immunology · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ajitanuj RattanNational Centre for Cell Science, S. P. Pune University Campus, Ganeshkhind, Pune, India.
Shailesh D PawarMicrobial Containment Complex, National Institute of Virology, Pune, India.
Renuka NawadkarNational Centre for Cell Science, S. P. Pune University Campus, Ganeshkhind, Pune, India.
Neeraja KulkarniNational Centre for Cell Science, S. P. Pune University Campus, Ganeshkhind, Pune, India.
Girdhari LalNational Centre for Cell Science, S. P. Pune University Campus, Ganeshkhind, Pune, India.ORCID 0000-0002-3799-3603
Jayati MullickMicrobial Containment Complex, National Institute of Virology, Pune, India.ORCID 0000-0002-8572-2867
Arvind SahuNational Centre for Cell Science, S. P. Pune University Campus, Ganeshkhind, Pune, India.ORCID 0000-0003-1664-2422
National Centre for Cell Science · INICMR-National Institute of Virology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pandemic influenza A(H1N1) 2009 virus caused significant morbidity and mortality worldwide thus necessitating the need to understand the host factors that influence its control. Previously, the complement system has been shown to provide protection during the seasonal influenza virus infection, however, the role of individual complement pathways is not yet clear. Here, we have dissected the role of intact complement as well as of its individual activation pathways during the pandemic influenza virus infection using mouse strains deficient in various complement components. We show that the virus infection in C3-/- mice results in increased viral load and 100% mortality, which can be reversed by adoptive transfer of naïve wild-type (WT) splenocytes, purified splenic B cells, or passive transfer of immune sera from WT, but not C3-/- mice. Blocking of C3a and/or C5a receptor signaling in WT mice using receptor antagonists and use of C3aR-/- and C5aR-/- mice showed significant mortality after blocking/ablation of C3aR, with little or no effect after blocking/ablation of C5aR. Intriguingly, deficiency of C4 and FB in mice resulted in only partial mortality (24%-32%) suggesting a necessary cross-talk between the classical/lectin and alternative pathways for providing effective protection. In vitro virus neutralization experiments performed to probe the cross-talk between the various pathways indicated that activation of the classical and alternative pathways in concert, owing to coating of viral surface by antibodies, is needed for its efficient neutralization. Examination of the virus-specific complement-binding antibodies in virus positive subjects showed that their levels vary among individuals. Together these results indicate that cooperation between the classical and alternative pathways not only result in efficient direct neutralization of the pandemic influenza virus, but also lead to the optimum generation of C3a, which when sensed by the immune cells along with the antigen culminates in generation of effective protective immune responses.

Indexed as

Adoptive TransferAnimalsAntibodies, ViralComplement Pathway, AlternativeComplement Pathway, ClassicalDisease Models, AnimalEnzyme-Linked Immunosorbent AssayFemaleHumansInfluenza A Virus, H1N1 SubtypeInfluenza, HumanMiceMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutNeutralization TestsAntibodies, Viral

Identifiers

PMID28301559
PMCPMC5354441
OpenAlexW2596669732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.